ReviewFrontiers in molecular neuroscience2024
Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics.
Review in Frontiers in molecular neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Effects of Transcranial Magnetic Stimulation on Patients with Major Depressive Disorder: A Systematic Review and Meta-analysis.Clinical medicine & research · 2026Pooled it
- Nose-brain axis: A bridge from the nasal cavity to the central nervous system.Neural regeneration research · 2026Article
- Headache Attributed to Genetic Vasculopathies.Current pain and headache reports · 2026Review
- Angiotensin-Converting Enzyme (ACE) Insertion/Deletion (I/D) Polymorphism and Migraine Susceptibility and Phenotypes: A Clinical-Genetic Study in a United Arab Emirates (UAE) Cohort.Journal of clinical medicine · 2026Article
- EGR1-associated inflammatory and neurovascular signatures suggest a potential link between migraine and ischemic stroke.The journal of headache and pain · 2026Article
- IL-17A, IL-17RA, and IL-22 as biomarkers in migraine: associations with disease activity and clinical features.Irish journal of medical science · 2026Article
- Serum serotonin and its association with glycaemic indices and haemoglobin in adults with migraine: a comparative cross-sectional study.BMC neurology · 2026Observational
- Migraine and menopause as converging factors in brain vulnerability: a hypothesis-driven perspective.The journal of headache and pain · 2026Review
- Review
- Nitric Oxide, Oxidative Stress and Endothelial Dysfunction in Migraine: Recent Advances and Molecular Mechanisms.International journal of molecular sciences · 2026Review
- Bridging the gap: molecular mechanisms, regional activity and connectivity in headache disorders.Brain : a journal of neurology · 2026Review
- Unraveling the Cross-Tissue Neuroimmune-Vascular Genetic Architecture of Migraine Using Integrated Multi-Omics, Single-Cell, and Spatial Transcriptomics: Prioritizing T-Cell Regulatory Networks and Peripheral Targets.International journal of molecular sciences · 2026Article
- Evaluation of the antimigraine and anti-neuroinflammatory activity of purified constituents of Petasites hybridus L. in a migraine-like pain model in mice.Inflammopharmacology · 2026Article
- Association between TNFa rs1800629 and migraine: Case-control study and updated meta-analysis.AIMS neuroscience · 2026Article
- Olfactory abnormalities in patients with migraine: a narrative review of a symptom commonly overlooked by neurologists.Journal of oral & facial pain and headache · 2025Review
- Acephalgic Migraine Presenting as Episodic Fatigue and Nausea: A Case Report.Clinical medicine & research · 2025Article
- Review
- Article
- Article
- The Role of Inflammation in Migraine Headaches: A Review.FASEB bioAdvances · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The individual and global burden of migraine is of such significance that there are accelerated efforts to develop new therapies. New migraine therapeutics are needed to address the current deficiencies that exist in the efficacy and adherence rate of approved anti-migraine medications. The recent discovery of the calcitonin gene related peptide as an add-on to the role of serotonin has markedly increased the range of new treatment options for acute and chronic migraine. Despite this, tackling the complexity of migraine disorders requires a complete understanding of its pathophysiology. Preclinical animal models can shed light on disease-related pathophysiology, including migraine. Indeed, the use of animal models has been instrumental in developing many therapeutics. However, an animal model is limited by the predictive and face validity of that model, and this extends to preclinical migraine models. In this review, a summary of the current understanding of the pathophysiology of migraine is given from both a preclinical and clinical perspective, and an emphasis is placed on the animal models of migraine. We will discuss the strengths and pitfalls of common preclinical migraine models as well as experimental research areas to explore further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.